Inogen Inc (NASDAQ:INGN) has received an average rating of “Hold” from the eleven analysts that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $61.75.
INGN has been the subject of a number of analyst reports. Piper Jaffray Companies decreased their price objective on Inogen from $140.00 to $80.00 and set an “overweight” rating for the company in a research note on Wednesday, August 7th. Needham & Company LLC cut Inogen from a “buy” rating to a “hold” rating in a research note on Wednesday, August 7th. Svb Leerink restated a “market perform” rating and set a $47.00 price objective (down from $78.00) on shares of Inogen in a research note on Thursday, August 8th. KeyCorp restated a “hold” rating on shares of Inogen in a research note on Wednesday, August 7th. Finally, Stifel Nicolaus cut Inogen from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $85.00 to $48.00 in a research note on Wednesday, August 7th.
Shares of NASDAQ INGN traded up $0.53 during mid-day trading on Monday, reaching $49.51. 389,367 shares of the company were exchanged, compared to its average volume of 567,912. The company has a quick ratio of 6.82, a current ratio of 7.35 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of 21.53, a P/E/G ratio of 4.09 and a beta of 1.51. Inogen has a 1 year low of $41.19 and a 1 year high of $205.34. The firm has a 50-day moving average of $47.42 and a 200 day moving average of $61.93.
Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Wednesday, August 7th. The medical technology company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). The company had revenue of $101.10 million for the quarter, compared to analysts’ expectations of $106.88 million. Inogen had a return on equity of 13.34% and a net margin of 11.24%. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.65 earnings per share. On average, equities analysts forecast that Inogen will post 1.09 earnings per share for the current year.
In other Inogen news, Director Heath Lukatch purchased 2,000 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was bought at an average cost of $43.01 per share, for a total transaction of $86,020.00. Following the completion of the purchase, the director now owns 5,481 shares in the company, valued at approximately $235,737.81. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Loren L. Mcfarland purchased 1,000 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was acquired at an average price of $42.93 per share, with a total value of $42,930.00. Following the completion of the purchase, the director now owns 4,481 shares of the company’s stock, valued at approximately $192,369.33. The disclosure for this purchase can be found here. Company insiders own 4.54% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in INGN. Formula Growth Ltd. raised its stake in Inogen by 61.8% in the first quarter. Formula Growth Ltd. now owns 13,088 shares of the medical technology company’s stock valued at $1,248,000 after buying an additional 5,000 shares during the last quarter. Marshall Wace LLP raised its stake in Inogen by 180.2% in the first quarter. Marshall Wace LLP now owns 55,580 shares of the medical technology company’s stock valued at $5,301,000 after buying an additional 35,747 shares during the last quarter. Riverbridge Partners LLC acquired a new position in shares of Inogen in the second quarter valued at about $18,623,000. Oregon Public Employees Retirement Fund increased its holdings in shares of Inogen by 3.5% in the second quarter. Oregon Public Employees Retirement Fund now owns 7,273 shares of the medical technology company’s stock valued at $486,000 after purchasing an additional 244 shares during the period. Finally, Fox Run Management L.L.C. acquired a new position in shares of Inogen in the second quarter valued at about $226,000.
Inogen Company Profile
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Featured Story: Options Trading – Understanding Strike Price
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.